Ehlers-Danlos Syndrome Genetic Test: COL5A1, COL5A2, COL3A1, and Results

An Ehlers-Danlos syndrome genetic test can confirm certain inherited connective tissue disorders, but it is not a single yes-or-no test for every form of EDS. COL5A1 and COL5A2 testing mainly evaluates classic Ehlers-Danlos syndrome, while COL3A1 testing evaluates vascular Ehlers-Danlos syndrome. These conditions can share bruising, flexible joints, and fragile tissues, yet their medical risks and care plans differ greatly. A carefully chosen test can clarify the subtype, guide family testing, and change precautions for surgery, pregnancy, vascular imaging, wound care, and emergency treatment. However, a negative panel does not rule out hypermobile Ehlers-Danlos syndrome, because no routinely accepted single genetic cause explains most hEDS cases. The best interpretation combines the laboratory report with a detailed medical history, physical examination, family history, and the laboratory’s testing methods. Results should be reviewed with a clinical geneticist or genetic counselor, especially when a COL3A1 variant, a variant of uncertain significance, or a mismatch between the result and symptoms is found.

• COL5A1 or COL5A2 pathogenic variants usually support classic EDS, especially when skin hyperextensibility, atrophic scars, bruising, and generalized joint hypermobility are present.
• A COL3A1 pathogenic variant usually confirms vascular EDS, which can cause arterial, intestinal, or uterine fragility and needs specialist management.
• A negative genetic panel does not exclude hypermobile EDS, because hEDS remains a clinical diagnosis in most people.
• The most complete testing usually includes sequencing plus deletion-and-duplication analysis, not just a small variant panel.
• A variant of uncertain significance does not confirm EDS and should not be used alone for major medical or reproductive decisions.
• Sudden severe chest, abdominal, head, or neck pain requires urgent care when vascular EDS is possible, particularly with fainting, weakness, major bleeding, or breathing difficulty.

Table of Contents

• Why This Is Not One General EDS Test
• What COL5A1, COL5A2, and COL3A1 Evaluate
• How Clinicians Choose and Perform Testing
• How to Read the Result Categories
• COL5A1 and COL5A2 Results in Classic EDS
• COL3A1 Results in Vascular EDS
• Negative, Uncertain, Mosaic, and Unexpected Results
• Family Testing, Pregnancy, and Next Steps

Why This Is Not One General EDS Test

The name “Ehlers-Danlos syndrome” describes a group of inherited connective tissue disorders rather than one disease caused by one gene. Connective tissue helps give strength and flexibility to skin, joints, blood vessels, organs, ligaments, and other structures. Different EDS types arise from defects in different collagen proteins or in proteins that process and organize collagen.

This matters because a test limited to COL5A1, COL5A2, and COL3A1 does not evaluate every genetic EDS type. It is mainly designed around two important diagnoses:

• Classic EDS, usually associated with COL5A1 or COL5A2
• Vascular EDS, usually associated with COL3A1

Other EDS types involve genes such as TNXB, AEBP1, PLOD1, FKBP14, ADAMTS2, B4GALT7, SLC39A13, and others. A broader connective tissue disorder panel may be more appropriate when the person has congenital hip dislocation, severe early scoliosis, marked muscle weakness, eye fragility, hearing loss, short stature, unusual facial or skeletal features, or findings that do not fit classic or vascular EDS.

Hypermobile Ehlers-Danlos syndrome is a common source of confusion. It can cause generalized joint hypermobility, instability, pain, soft skin, and fatigue, yet routine molecular testing does not confirm most hEDS cases. Testing based only on flexibility often produces a negative report or an uncertain variant.

Clinical evaluation should occur before or alongside testing. Joint mobility, skin and scar findings, bruising, vascular or organ events, age at onset, skeletal features, and family history help determine whether to target COL5A1 and COL5A2, prioritize COL3A1, or use a wider connective tissue panel.

What COL5A1, COL5A2, and COL3A1 Evaluate

COL5A1 and COL5A2 provide instructions for components of type V collagen. Type V collagen is present in smaller amounts than some other collagens, but it helps control the formation and diameter of collagen fibers. When it is altered, skin, ligaments, and other tissues may lose normal strength and organization.

A disease-causing change in one copy of COL5A1 or COL5A2 usually causes classic EDS in an autosomal dominant pattern. One altered copy can be enough to cause the condition. COL5A1 variants often reduce the amount of functional type V collagen. Many COL5A2 variants produce an abnormal collagen chain that interferes with collagen assembly. The exact mechanism can influence how the laboratory evaluates a variant, but symptoms still vary among people with the same gene and even within one family.

Classic EDS is most strongly suggested by the combination of:

• Skin that stretches more than expected and returns after release
• Wide, thin, or sunken-looking atrophic scars
• Fragile skin that splits after relatively minor trauma
• Easy bruising
• Generalized joint hypermobility
• Recurrent sprains, dislocations, or joint pain
• Poor wound healing or widened scars after surgery

COL3A1 provides instructions for type III collagen, an important structural protein in arteries, bowel, uterus, lungs, skin, and other hollow or distensible tissues. A pathogenic variant in one COL3A1 copy usually causes vascular EDS through autosomal dominant inheritance.

Vascular EDS can present differently from classic EDS. Many affected people do not have striking generalized joint hypermobility or highly stretchy skin. Clues can include thin translucent skin, easy bruising in unusual locations, visible veins, characteristic facial features, small-joint hypermobility, clubfoot, tendon or muscle rupture, early varicose veins, spontaneous pneumothorax, bowel perforation, or an arterial aneurysm, dissection, fistula, or rupture at a young age.

Variant type can influence vascular EDS on average, but it cannot predict one person’s exact course. Care should follow the individual’s history and findings rather than a “mild” or “severe” label based only on genotype.

A report may include all three genes because bruising, skin findings, and joint hypermobility can overlap. That panel design is useful, but interpretation must still identify which phenotype fits the detected variant. A COL3A1 result should not be treated as interchangeable with a COL5A1 result, because the complications and medical precautions differ.

How Clinicians Choose and Perform Testing

Testing usually begins with a blood or saliva sample. Blood is often preferred when mosaicism is a concern or when the laboratory’s validated method performs best with high-quality DNA. The person generally does not need to fast, stop medication, or change activity before collection.

The laboratory may use a single-gene test, a small EDS panel, a broader hereditary connective tissue panel, exome sequencing, or genome sequencing. The choice depends on how specific the clinical picture is.

A focused COL3A1 test can be appropriate when vascular EDS is strongly suspected. COL5A1 and COL5A2 testing may be reasonable when the classic EDS criteria are clearly met. A multigene panel is often more efficient when symptoms overlap several conditions, such as Loeys-Dietz syndrome, Marfan syndrome, familial thoracic aortic disease, osteogenesis imperfecta, cutis laxa, or another EDS subtype.

Sequencing

DNA sequencing reads the gene’s coding regions and nearby splice boundaries. It is designed to detect single-letter changes and small insertions or deletions. Most pathogenic variants in COL3A1, COL5A1, and COL5A2 can be found by well-designed sequencing, but coverage and analytical methods differ among laboratories.

A report should state which transcript was used, which regions were analyzed, and whether low-coverage areas were completed by another method. It should also explain whether the assay can detect low-level mosaic variants, deep intronic changes, or other alterations outside standard coding regions.

Deletion-and-duplication analysis

Sequencing alone can miss the loss or gain of one or more exons, or larger changes involving an entire gene. Deletion-and-duplication analysis looks for these copy-number variants. Such variants are not the most common explanation for these EDS types, but including copy-number analysis makes the evaluation more complete.

Some next-generation sequencing panels calculate copy number from sequencing data. Others use methods such as multiplex ligation-dependent probe amplification. The report should clearly state whether copy-number analysis was performed rather than leaving the reader to assume it was included.

RNA, fibroblast, or extended testing

A DNA change near a splice site may be difficult to classify because its effect on RNA is uncertain. In selected cases, RNA testing can show whether the variant causes abnormal splicing. Testing cultured skin fibroblasts or another suitable tissue may help when the relevant RNA is not expressed well in blood.

When a person has convincing classic EDS features but routine COL5A1 and COL5A2 analysis is negative, a specialist may consider RNA studies, genome sequencing, reanalysis, or testing additional genes. These methods are not automatically needed for everyone. They are most useful when the clinical findings create a strong, specific hypothesis that standard testing did not resolve.

How to Read the Result Categories

Genetic reports usually classify each variant as pathogenic, likely pathogenic, uncertain significance, likely benign, or benign. The category describes the evidence that the variant causes disease; it does not directly measure how severe a person’s symptoms will be.

Result	Usual meaning	Typical response
Pathogenic or likely pathogenic variant	The variant is considered disease-causing or very likely disease-causing when the gene and phenotype fit.	Confirm the subtype, arrange condition-specific care, and offer targeted family testing.
Variant of uncertain significance	Evidence is insufficient or conflicting; the variant may later be reclassified.	Do not use it alone to confirm EDS. Compare symptoms, inheritance, databases, and possible functional evidence.
Negative	No reportable pathogenic variant was found by the methods used.	Review whether the right genes and variant types were tested and whether a clinical diagnosis still applies.
Benign or likely benign variant	The change is not considered a cause of EDS.	No EDS-specific action is based on that variant.
Pathogenic variant in an unexpected gene	The test may have identified another connective tissue disorder or a different EDS subtype.	Reassess the phenotype and use management guidance for the actual gene and condition.

A positive result is strongest when three pieces agree: the variant has convincing evidence, the gene is associated with the suspected condition, and the person’s clinical findings fit that condition. A pathogenic COL5A1 variant in someone with classic skin and scar findings is highly informative. The same variant found incidentally in someone without compatible features still deserves expert review, but the clinician may need to examine penetrance, mosaicism, laboratory evidence, and whether the variant classification is current.

A variant may be de novo, meaning it was not found in either parent’s blood. A small recurrence risk can remain because a parent may have the variant only in some egg or sperm cells.

The laboratory may also report an allele fraction, the percentage of sequence reads containing the variant. A value substantially below the expected level for a standard heterozygous result may suggest mosaicism, sample quality issues, or a technical artifact. The laboratory should confirm a possible mosaic result and explain the assay’s detection limit.

COL5A1 and COL5A2 Results in Classic EDS

A pathogenic or likely pathogenic variant in COL5A1 or COL5A2 generally establishes a molecular diagnosis of classic EDS when the clinical findings are consistent. In people with the full characteristic skin phenotype, most have an identifiable pathogenic variant in one of these genes. Detection rates are lower when skin findings are mild, scars are not clearly atrophic, or the presentation mainly involves joint hypermobility and pain.

The result can explain why ordinary injuries produce unusually wide scars, why stitches may pull through fragile skin, and why joints move beyond the expected range. It also supports practical adjustments:

• Wounds may need careful closure with minimal tension and longer support than usual.
• Physical therapy should emphasize controlled strengthening and joint stability rather than pushing flexibility.
• Contact sports and activities with repeated high-impact joint or skin trauma may need modification.
• Bruising or prolonged bleeding should be assessed clinically rather than assumed to be harmless.
• Surgeons, dentists, physical therapists, and other clinicians should know the diagnosis before procedures.

Classic EDS can involve more than skin and joints. Some people have hernias, pelvic organ prolapse, fatigue, pain, or mild cardiovascular findings. Management should follow actual symptoms and specialist assessment rather than an automatic schedule copied from another EDS type.

A COL5A1 or COL5A2 result does not predict exact pain, dislocation frequency, or wound healing. Even relatives with the same variant can differ.

When a person has one pathogenic variant and one uncertain variant in the same gene, the pathogenic variant may already explain an autosomal dominant condition. The uncertain finding should not automatically be treated as a second disease-causing change or as proof of greater severity. The laboratory and genetics team should determine whether the second variant adds meaningful information.

A negative COL5A1 and COL5A2 result weakens, but does not always eliminate, a suspected classic EDS diagnosis. The next step depends on how well the person meets clinical criteria and how complete the assay was. A broad panel may reveal another EDS type or a related disorder. In a strongly characteristic case, a genetics specialist may discuss RNA testing, analysis for structural variants, or future reanalysis.

COL3A1 Results in Vascular EDS

A pathogenic or likely pathogenic COL3A1 variant usually confirms vascular EDS. This result has immediate medical value because serious complications can occur without a large, previously known aneurysm. Arteries, bowel, lungs, and other tissues may be fragile, and routine procedures can carry different risks than they do in the general population.

After confirmation, care is best coordinated through clinicians familiar with vascular EDS. The plan may include noninvasive arterial imaging, blood pressure assessment, individualized activity guidance, an emergency information letter, and review of medications or procedures. The exact imaging method and interval depend on age, prior vascular findings, family history, local expertise, and the balance between useful surveillance and procedural burden.

Invasive arterial angiography, unnecessary arterial puncture, and elective procedures should be considered carefully because tissue injury can cause complications. This does not mean that a person should refuse lifesaving surgery or urgent treatment. It means the treating team should know about vEDS, use experienced specialists when possible, choose less invasive approaches when medically suitable, and prepare for fragile vessels and tissues.

Emergency symptoms deserve direct action. A person with known or suspected vascular EDS should seek urgent evaluation for sudden severe chest, abdominal, flank, back, head, or neck pain; stroke-like symptoms; fainting or collapse; major unexplained bleeding; a rapidly enlarging painful swelling; or sudden shortness of breath. The emergency team should be told that vascular EDS is confirmed or suspected. Not every episode is a rupture or dissection, but dangerous causes must be considered promptly.

Pregnancy requires preconception counseling and management by a high-risk obstetric team with vascular and genetics input. Vascular, uterine, cervical, and tissue complications can occur during pregnancy, delivery, or the postpartum period. Risk is not identical for every person, and the safest plan depends on the individual’s variant, medical history, vascular findings, prior pregnancies, and goals.

COL3A1 reports may describe a glycine substitution, splice variant, in-frame deletion, null variant, or another mechanism. These categories can provide context, but substantial overlap remains, so care should not be relaxed solely because a variant has been linked to later complications on average.

A COL3A1 variant of uncertain significance is especially challenging because labeling someone with vascular EDS can affect surgery, pregnancy choices, insurance concerns, anxiety, and family testing. The diagnosis should not rest on the VUS alone. Detailed phenotype review, testing affected relatives, checking whether the variant tracks with disease, RNA or protein studies when available, and periodic reclassification may help resolve it.

Negative, Uncertain, Mosaic, and Unexpected Results

A negative result means the laboratory did not find a reportable disease-causing variant within the parts of the genes and variant types it could assess. It does not mean the connective tissue is normal, and it does not erase clinical findings.

Several explanations are possible:

• The person may have hypermobile EDS, which usually lacks a confirmatory clinical genetic test.
• Another EDS gene or related connective tissue gene may be responsible.
• The causal change may lie in a region the assay did not cover well.
• A structural, deep intronic, regulatory, or low-level mosaic variant may have been missed.
• Current science may not yet connect the responsible gene or variant to disease.
• The symptoms may arise from a non-EDS condition, acquired injury, another genetic syndrome, or more than one diagnosis.

A negative result is therefore interpreted against the pretest probability. If the initial clinical suspicion was weak and based only on common flexibility, a negative panel may end the molecular workup. If a young person has spontaneous arterial rupture, translucent skin, characteristic bruising, and a family history of early vascular death, a negative basic COL3A1 test should trigger a close review of assay coverage and alternative vascular genes.

A VUS should be treated as unresolved information. Testing healthy relatives merely to see who carries it is often unhelpful unless the laboratory or genetics team has designed a segregation study that can contribute evidence. Medical treatment should follow the person’s demonstrated risks and clinical diagnosis while the variant remains uncertain.

Mosaicism means the variant is present in some cells but not all. A person with somatic mosaicism may have milder, patchy, or atypical findings, although severity cannot be predicted from a blood percentage alone. A parent with low-level mosaicism may have few signs yet still pass the variant to a child. When suspicion remains high, testing another tissue or using a method with deeper read coverage may be considered.

Unexpected results require careful phenotype review. A broad panel may find a pathogenic variant in a gene linked to Loeys-Dietz syndrome, hereditary thoracic aortic disease, osteogenesis imperfecta, or another EDS subtype. The correct response is not to force the finding into the original label. The diagnosis, surveillance, family risk, and pregnancy counseling should follow the identified condition.

Variant classifications change. Contact the laboratory or genetics clinic when new findings arise or several years have passed, because not every laboratory automatically issues an amended report.

Family Testing, Pregnancy, and Next Steps

Classic EDS caused by COL5A1 or COL5A2 and vascular EDS caused by COL3A1 are usually autosomal dominant. An affected person generally has a 50% chance of passing the familial variant to each child. The probability is the same in each pregnancy and does not depend on the child’s sex.

A new diagnosis in one person can clarify risk across an entire family. The most efficient approach is targeted testing for the exact familial variant rather than ordering a full panel for every relative. Relatives who test positive can receive subtype-specific evaluation and precautions. Relatives who test negative for a well-established familial variant usually do not have the inherited condition caused by that variant, although unrelated symptoms still need their own clinical assessment.

Family testing should begin with the person most clearly affected whenever possible. Testing an unaffected relative first can produce an uncertain result without revealing the cause of the family’s symptoms. If the affected relative is deceased, stored tissue, prior medical records, autopsy findings, or testing another affected family member may help.

Once a familial pathogenic variant is known, reproductive options can include natural conception with or without prenatal diagnosis, in vitro fertilization with preimplantation genetic testing for a monogenic condition, use of donor egg or sperm, adoption, or choosing not to pursue pregnancy. Chorionic villus sampling and amniocentesis can test a pregnancy for the known familial variant. Screening tests based on ultrasound or routine cell-free DNA do not reliably replace diagnostic testing for these single-gene conditions.

Prenatal testing usually predicts whether the variant is present, not the child’s exact severity. Pregnancy can also affect an affected parent’s health, especially with vascular EDS, so counseling should address both inheritance and maternal risk.

After any report, useful questions for the genetics appointment include:

• Does the gene and variant fit my specific clinical findings?
• Did the laboratory perform both sequencing and deletion-and-duplication analysis?
• Could this result represent mosaicism?
• Does the result confirm a subtype, or is the diagnosis still clinical?
• Which relatives should receive targeted testing first?
• What changes are needed before surgery, dental procedures, pregnancy, or strenuous activity?
• Which symptoms need emergency evaluation?
• Will the laboratory notify us if the variant is reclassified?

The result should become part of a living care plan rather than remain an isolated laboratory document. Keep a copy of the full report, not just a patient-portal summary. Record the gene, exact variant, classification, laboratory, and report date. Share the diagnosis with relevant clinicians, and ask the genetics team for an updated letter when interpretation or management changes.

References

• Classic Ehlers-Danlos Syndrome 2024 (Clinical Review)
• Vascular Ehlers-Danlos Syndrome 2025 (Clinical Review)
• Genetic diagnosis of the Ehlers-Danlos syndromes 2024 (Review)
• Diagnosis and management of vascular Ehlers-Danlos syndrome: Experience of the UK national diagnostic service, Sheffield 2023 (Clinical Review)
• Hypermobile Ehlers-Danlos Syndrome 2024 (Clinical Review)
• Ehlers-Danlos syndromes: importance of defining the type 2024 (Review)

Disclaimer

This article provides general information and does not diagnose Ehlers-Danlos syndrome or replace care from a clinical geneticist, genetic counselor, vascular specialist, or other qualified professional. Genetic results must be interpreted with the person’s symptoms, family history, and the laboratory’s methods. Sudden severe pain, stroke-like symptoms, collapse, major bleeding, or breathing difficulty requires urgent medical evaluation, particularly when vascular EDS is known or suspected.